Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.38)
# 2,539
Out of 5,115 analysts
136
Total ratings
50.59%
Success rate
-2.24%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Outperform | $50 | $44.20 | +13.12% | 1 | Jan 12, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $14 → $25 | $16.81 | +48.72% | 11 | Jan 6, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $28 → $30 | $23.22 | +29.20% | 5 | Nov 7, 2025 | |
| OMDA Omada Health | Maintains: Outperform | $27 → $28 | $14.95 | +87.29% | 1 | Nov 7, 2025 | |
| DOCS Doximity | Maintains: Outperform | $81 → $70 | $37.47 | +86.82% | 10 | Nov 7, 2025 | |
| HSIC Henry Schein | Maintains: Outperform | $83 → $90 | $75.48 | +19.24% | 2 | Nov 5, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $190 → $220 | $214.88 | +2.38% | 10 | Oct 31, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $9 → $8 | $5.45 | +46.79% | 6 | Oct 30, 2025 | |
| CVS CVS Health | Maintains: Outperform | $85 → $95 | $74.52 | +27.48% | 10 | Oct 30, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $160 → $170 | $163.03 | +4.28% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $17 → $13 | $12.47 | +4.25% | 8 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $240 | $230.15 | +4.28% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $34.90 | +86.25% | 2 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $2.15 | +39.53% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $185 → $190 | $187.03 | +1.59% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $305 | $271.52 | +12.33% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $831.21 | -0.75% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $23.47 | -2.00% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.83 | +260.49% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $26.56 | +35.54% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $2.16 | +1,115.28% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $2.83 | +430.04% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $1.42 | +674.65% | 2 | Jan 4, 2022 |
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $50
Current: $44.20
Upside: +13.12%
Fortrea Holdings
Jan 6, 2026
Upgrades: Outperform
Price Target: $14 → $25
Current: $16.81
Upside: +48.72%
Privia Health Group
Nov 7, 2025
Maintains: Outperform
Price Target: $28 → $30
Current: $23.22
Upside: +29.20%
Omada Health
Nov 7, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $14.95
Upside: +87.29%
Doximity
Nov 7, 2025
Maintains: Outperform
Price Target: $81 → $70
Current: $37.47
Upside: +86.82%
Henry Schein
Nov 5, 2025
Maintains: Outperform
Price Target: $83 → $90
Current: $75.48
Upside: +19.24%
Cardinal Health
Oct 31, 2025
Maintains: Outperform
Price Target: $190 → $220
Current: $214.88
Upside: +2.38%
Teladoc Health
Oct 30, 2025
Maintains: In-Line
Price Target: $9 → $8
Current: $5.45
Upside: +46.79%
CVS Health
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $74.52
Upside: +27.48%
Align Technology
Oct 30, 2025
Maintains: Outperform
Price Target: $160 → $170
Current: $163.03
Upside: +4.28%
Oct 8, 2025
Maintains: In-Line
Price Target: $17 → $13
Current: $12.47
Upside: +4.25%
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $230.15
Upside: +4.28%
Oct 8, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $34.90
Upside: +86.25%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $2.15
Upside: +39.53%
Oct 8, 2025
Maintains: In-Line
Price Target: $185 → $190
Current: $187.03
Upside: +1.59%
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $271.52
Upside: +12.33%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $831.21
Upside: -0.75%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $23.47
Upside: -2.00%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.83
Upside: +260.49%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $26.56
Upside: +35.54%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $2.16
Upside: +1,115.28%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $2.83
Upside: +430.04%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $1.42
Upside: +674.65%